HKINOEN GLP1 series once-weekly obesity treatment approved by the Ministry of Food and Drug Safety for phase 3 clinical trials in Korea
May 08, 2025
|
The global obesity treatment market is expected to grow 14.4% annually to $19.37 billion (about 26.5813 trillion won) in 2023, reaching $37.367.1 billion (about 52.1457 trillion won) in 2028.
The number of obese people in Korea is also increasing. According to the 「Bobesity Fact Sheet 2024" published by the Korean Society of Obesity, the prevalence of obesity among all adults in Korea has been continuously increasing to 38.4% over the past 10 years until 2022.
As a result, the demand for obesity treatments is also increasing, and in this situation, HKINON is entering phase 3 clinical trials for obesity treatments.
HKINOEN announced on the 7th that it has received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial plan (IND) for 'IN-B00009 (component name: Eknoglutide), which is being developed as a GLP-1 receptor agonist-based obesity treatment.
The phase 3 clinical trial will be conducted in adult obese or overweight patients without diabetes, and IN-B00009 or placebo is administered once a week as a subcutaneous injection to evaluate its effectiveness and safety. The trial is designed in a multicenter, randomized, double-blind, placebo-controlled, parallel-group manner and aims to be completed in May 2028.
In this test, HKINOEN set the weight change rate at 40 weeks compared to the baseline and the proportion of test subjects with a weight loss rate of 5% or more as the primary endpoint.
IN-B00009 is a family of glucagon-like peptide-1 receptor agonists (Glucagon-Like Peptide-1 Receptor Agonists) introduced by HKINOEN in 2024 by Chinese biotechnology company SCIWIND BIOSCIENCES CO., LTD. HKINOEN has secured the right to develop and commercialize the substance in Korea and is developing it as a treatment for obesity and diabetes. NB00009 has previously demonstrated safety and statistically significant weight loss compared to liraglutide when administered at 26 weeks in phase 2 clinical trials in obese patients in Australia and New Zealand. In addition, phase 3 clinical trials for obese patients in China have also confirmed superior weight loss effects compared to placebo.
A HKINOEN official said "We will focus all our capabilities to help IN-B00009 contribute to the treatment of obesity, a worldwide disease."
This article was translated by Naver AI translator.
